Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure

European Heart Journal Cardiovascular Imaging

Volumn 16, Issue 10, 2015, Pages 1148-1153

  Paolillo, S ^a,b   Rengo, G ^b,c   Pellegrino, T ^b,d   Formisano, R ^b   Pagano, G ^b   Gargiulo, P ^a   Savarese, G ^b   Carotenuto, Rita ^b   Petraglia, L ^b   Rapacciuolo, A ^b   Perrino, C ^b   Piscitelli, S ^b   Attena, E ^e   Del Guercio, L ^b   Leosco, D ^b   Trimarco, B ^b   Cuocolo, A ^a,b   Perrone Filardi, P ^b  

^a IRCCS SDN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS   (Italy)

^d CNR   (Italy)

^e Department of Cardiology Fatebenefratelli Hospital ^*  (Italy)

Author keywords

123I MIBG; Cardiac sympathetic innervation; Heart failure; Insulin resistance

Indexed keywords

(3 IODOBENZYL)GUANIDINE; INSULIN; IODINE 123; BIOLOGICAL MARKER; RADIOPHARMACEUTICAL AGENT;

ADRENERGIC SYSTEM; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART; HEART FAILURE; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; INSULINEMIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MYOCARDIAL PERFUSION IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYMPATHETIC INNERVATION; BLOOD; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; SCINTISCANNING; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

3-IODOBENZYLGUANIDINE; AGED; BIOMARKERS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MALE; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84941776468     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jev061     Document Type: Article

References (25)

1. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-26.
2. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87:2246-52.
3. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161-8.
4. Ziegler D, Weise F, Langen KJ, Piolot R, Boy C, Hübinger A et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41:443-51.
5. Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Femminella GD et al. Impact of diabetes mellitus on cardiac sympathetic innervation in patients with heart failure: A 123I meta-iodobenzylguanidine (123IMIBG) scintigraphic study. Diabetes Care 2013;36:2395-401.
6. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. Myocardial iodine-123-metaiodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108.
9. Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-12.
10. Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R et al. Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging 2013;40:1549-57.
11. Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C et al. Targeting b-adrenergic receptor system via G-protein coupled receptor kinase 2 (GRK2): a new paradigm for therapy and prognostic evaluation in heart failure. From bench to bedside. Circ Heart Fail 2012;5:385-91.
12. Mongillo M, John AS, Leccisotti L, Pennell DJ, Camici PG. Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart. Eur J Nucl Med Mol Imaging 2007;34:1172-7.
13. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995;25:610-8.
14. Yufu K, Takahashi N, Okada N, Shinohara T, Nakagawa M, Hara M et al. Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease. Circ J 2012;76:399-404.
15. Takahashi N, Nakagawa M, Saikawa T, Ooie T, Yufu K, Shigematsu S et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232-7.
16. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 2005;96:180-8.
17. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ et al. G proteincoupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011;123:1953-62.
18. Das UN. Insulin: an endogenous cardioprotector. Curr Opin Crit Care 2003;9:375-83.
19. Yu QJ, Si R, Zhou N, Zhang HF, Guo WY, Wang HC et al. Insulin inhibits beta-adrenergic action in ischemic/reperfused heart: a novel mechanism of insulin in cardioprotection. Apoptosis 2008;13:305-17.
20. Yu J, Zhang HF, Wu F, Li QX, Ma H, Guo WY et al. Insulin improves cardiomyocyte contractile function through enhancement of SERCA2a activity in simulated ischemia/reperfusion. Acta Pharmacol Sin 2006;27:919-26.
21. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolismin patients with advanced heart failure. Circulation 2012;125:2844-53.
22. Al Zadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009;53:747-53.
23. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. JAmColl Cardiol 2006;48:2225-31.
24. Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J 2010;31:100-11.
25. Remme WJ. The sympathetic nervous system and ischaemic heart disease. Eur Heart J 1998;19:F62-71.